Clinical Trial Services Market worth $101.86 billion by 2030
The report "Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global Forecast to 2030", global clinical trial services market is projected to reach USD 101.86 billion by 2030, growing from USD 66.59 billion in 2025 at a CAGR of 8.9%. Growth is driven by the increasing adoption of patient-centric trials, including decentralized clinical trials (DCTs), and the rising demand for personalized medicine, supported by higher R&D investments. Major pharmaceutical companies facing a patent cliff are investing heavily in drug development, leading to increased outsourcing to CROs such as IQVIA, Icon PLC, and Parexel, which offer flexible services and integrate AI, real-world data, and adaptive trial designs to improve efficiency. Additionally, the expansion of pediatric clinical trials and the growing use of real-world data (RWD) for regulatory approvals are creating new opportunities for CROs. The rising emphasis on diverse patient populations, driven by FDA and EMA guidelines, is further increasing demand for CROs with a global presence. However, challenges such as cybersecurity risks associated with AI-driven data analysis and concerns over patient data protection remain key issues. Additionally, patient retention in long-duration trials continues to be a challenge, particularly for DCTs, where maintaining engagement is essential.
Browse 661 market data Tables and 61 Figures spread through 521 Pages and in-depth TOC on "Clinical Trial Services Market by Type (Laboratory, Monitoring, Recruitment, PV, Data Management), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/clinical-trials-market-405.html
The small molecules segment accounted for the largest share of the clinical trial services market, by modality, during the forecast period.
Based on modality, the clinical trial services market is divided into small molecules, biologics, and medical devices. The large share of the small molecules clinical trial segment can be attributed to the established role of these drug modalities in drug development across various therapeutic areas. Small molecules have a high oral bioavailability, making them more convenient for patients compared to biologics. Additionally, pharmaceutical companies continue to invest in small molecule research due to their cost-effectiveness, stability, and ability to target intracellular pathways, maintaining their dominance in clinical trials.
The oncology subsegment accounted for the largest share of the clinical trial service’s therapy area segment in 2024
Based on therapy area, the clinical trial services market is segmented into oncology, neurology, infectious diseases, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the clinical trial services market by therapy area in 2024. The large share of this segment is attributed to the increase in global cancer cases due to aging populations and lifestyle factors, supported by rising demand for new treatments. For this reason, pharmaceutical companies are increasingly investing and collaborating with CROs to develop advanced oncology drugs. This dominance is expected to continue throughout the forecast period as major players are developing new technologies for better oncology treatment.
Asia Pacific is registered as the fastest-growing region of the Clinical trials services market in 2024.
The clinical trial services market is divided into six regions, North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2024, North America held the largest share of the clinical trial services market, followed by Europe. Aisa Pacific registered the highest CAGR growth within the clinical trial services market during the forecast period owing to its large patient population, high prevalence of chronic and infectious diseases, and increasing focus on developing biologics, biosimilars, and advanced therapies. Global pharmaceutical companies are increasingly relocating manufacturing and clinical research to the region to leverage cost benefits, regulatory advancements, and improved patient retention in trials. Additionally, government support and rising investments in clinical research have further accelerated the outsourcing of clinical trial activities to APAC.
Key players in the clinical trial services market include IQVIA Inc. (US), Thermo Fisher Scientific Inc. (US), Fortrea (US), ICON Plc (Ireland), Syneos Health (US), Laboratory Corporation of America Holdings (US), Medpace (US), Wuxi AppTec (China), Frontage Labs (US), Pharmaron (US), Tigermed (China), SGS Société Générale De Surveillance SA. (Switzerland), Eurofins Scientific (Luxembourg), Linical (Japan), Parexel International Corporation (US), Worldwide Clinical Trials (US), Novotech (Australia), PSI (Switzerland), Allucent (US), Premier Research (US), Clario (US), KCR S.A. (US), Rho, Inc. (US) and Advanced Clinical (US) among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Clinical Trial Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
